AOA Dx Files US Patent (No. 63,087427) for the identification of gangliosides as markers for ovarian cancer
AOA DX Inc is pleased to announce it has filed a US Patent (No. 63,087427) for the compositions and methods of ovarian cancer diagnosis. This is an important step in making a cost-effective, accurate and simple liquid-biopsy test for ovarian cancer diagnosis widely available. The application gives 20 years of patent protection for the methods, lasting until at least 2040. The filing protects the intervention of accurate detection of ovarian cancer.
AOA Dx signs exclusive option agreement to commercialize cancer diagnosis technology from Professor Uri Saragovi, Senior Investigator with the Lady Davis Institute at the Jewish General Hospital and Professor at McGill University
AOA Dx Inc announces that it has signed an exclusive option agreement with Prof. Uri Saragovi providing exclusivity to develop and commercialize new cancer diagnostic technology. Ovarian cancer is the most lethal gynecologic cancer and the third cause of death in women. Tumors are classified based on cell type and further subdivided into benign, borderline and malignant (carcinomas), according to the aggressiveness. High Grade Serous Ovarian Cancer (HGSOC) is the most malignant and is labelled “the silent killer”. Symptoms are vague and easily confounded with other conditions. More than 70% of patients present to the clinic at advanced stages of disease, when surgical and therapeutic treatments become ineffective at extending life-span.